With urelumab plus rituximab, 72% of patients experienced a TRAE (grade 3/4, 28%; Table 2), with the most frequently reported events (≥10% of any grade) being fatigue (any grade, 20%; grade 3/4, 2%), increased AST (any grade, 15%; no grade 3/4 events), increased ALT (any grade, 13%; grade 3/4, 2%), neutropenia (any grade, 13%; grade 3/4, 11%), thrombocytopenia (any grade, 11%; grade 3/4, 4%), and nausea (any grade, 11%; no grade 3/4 events). Here, GPT is linked to Thrombocytopenia.